
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc is positioned for significant revenue growth, particularly with its Signatera product, which has shown remarkable performance with a 54% year-over-year volume increase and a quarterly increase of 21,500 patients tested. The company has also reported a strong quarterly revenue beat of approximately $80 million and has raised its revenue guidance for 2025 by $160 million, indicating robust financial expectations. Furthermore, the potential expansion of reimbursement coverage in oncology could enhance average selling prices, improve gross margins, and positively impact operating cash flow.
Bears say
Natera faces a negative outlook primarily due to anticipated erosion of margins stemming from reductions in in-network pricing as the addressable market expands, which may include a higher proportion of average risk patients. Compounding these challenges, any unfavorable developments in regulatory approvals, reimbursement processes, or financial performance could lead to significant stock price declines. Furthermore, uncertainties regarding the adoption of its products in international markets and potential setbacks in securing reimbursement coverage exacerbate the risks associated with Natera's growth and profitability.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares